Protocols

On a shopping spree, Allergan bags CoolSculpting tech in $2.5B buyout; Akebia strikes research deal with J&J

• Botox-maker Allergan has bagged a new company for its medical aesthetics portfolio, paying $2.47 billion for Pleasanton, CA-based Zeltiq Aesthetics $ZLTQ. Zeltiq made its rep with what it calls “CoolSculpting” tech, eliminating pockets of fat by cooling down fat cells. Allergan has been on a shopping spree for more than a year now as it builds up a pipeline of new drugs alongside its aesthetics business.

• Akebia $AKBA has gained entry to J&J’s hypoxia-inducible factor compound portfolio, with the right to pick out HIF therapies for development. The deal includes rights to one preclinical drug, JNJ5169, for inflammatory bowel disease. Akebia is paying $1 million upfront to start the deal and committed up to $16.5 million in development milestones and a potential $215 million for commercial goals.

• In a letter to Allergan, the SEC says that it plans to launch an investigation into the ways in which the biopharma industry may be exploiting non-GAAP accounting measures.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 31,500+ biopharma pros who read Endpoints News by email every day.

Free Subscription


Chief Medical Officer
Skyhawk Therapeutics Waltham, MA
Chief of Staff, North America
Ipsen Biopharmaceuticals Cambridge, MA
Senior Director, NA Digital Customer Interaction
Ipsen Biopharmaceuticals Cambridge, MA
GMP Supervisor - Downstream
Molecular Templates Austin, TX
Quality Control (QC) Associate
Molecular Templates Austin, TX

Visit Endpoints Careers ->